FATE241220C2000
- 1.24
- +0.34+37.78%
Fate Therapeutics Newsroom
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
Fate Therapeutics to Present at Upcoming December Investor Conferences
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Express News | Fate Therapeutics Inc : BofA Global Research Raises to Neutral From Underprform
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $10
Needham Reiterates Hold on Fate Therapeutics
Barclays Releases a Buy Rating on Fate Therapeutics (FATE)
Fate Therapeutics Hold Rating: Promising Early Results Amidst Developmental Challenges
Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
Fate Stock Rallies 37% on Positive Phase 1 Data for FT819, FT522
Fate Therapeutics Shares Halted On Circuit Breaker To Upside, Stock Now Up 70.8%
Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study With Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Earnings Beat: Fate Therapeutics, Inc. (NASDAQ:FATE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $6
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
Fate Therapeutics' Stock Volatility: Impact of Partnerships and Regulatory Challenges
Fate Therapeutics Unveils Q3 2024 Financial Highlights
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus